Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally

Stock Track

May 28

SKB BIO's stock price plummeted 5.02% during intraday trading on Thursday, marking a significant downward movement for the biopharmaceutical company.

The sharp decline follows a period of strong performance driven by positive clinical data presented at the ASCO annual meeting and a target price increase by Nomura. However, recent reports highlighting a broader deceleration within the Kelun group have prompted investors to reassess the company's fundamentals, leading to profit-taking. This reassessment was triggered by SKB BIO's 2025 financial results, which showed revenue growth of 6.5% year-over-year but a widening of net losses to 382 million yuan from 267 million yuan, as authorization and milestone income declined significantly while research and commercialization expenses remained high.

The sell-off in SKB BIO also occurred amid general weakness in the biotechnology sector during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1113614353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113614353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113614353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113614353","market":"us","top_or_hot":-1,"title":"Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally","media":"Stock Track","content":"<p>SKB BIO's stock price plummeted 5.02% during intraday trading on Thursday, marking a significant downward movement for the biopharmaceutical company.</p><p>The sharp decline follows a period of strong performance driven by positive clinical data presented at the ASCO annual meeting and a target price increase by Nomura. However, recent reports highlighting a broader deceleration within the Kelun group have prompted investors to reassess the company's fundamentals, leading to profit-taking. This reassessment was triggered by SKB BIO's 2025 financial results, which showed revenue growth of 6.5% year-over-year but a widening of net losses to 382 million yuan from 267 million yuan, as authorization and milestone income declined significantly while research and commercialization expenses remained high.</p><p>The sell-off in SKB BIO also occurred amid general weakness in the biotechnology sector during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-28 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SKB BIO's stock price plummeted 5.02% during intraday trading on Thursday, marking a significant downward movement for the biopharmaceutical company.</p><p>The sharp decline follows a period of strong performance driven by positive clinical data presented at the ASCO annual meeting and a target price increase by Nomura. However, recent reports highlighting a broader deceleration within the Kelun group have prompted investors to reassess the company's fundamentals, leading to profit-taking. This reassessment was triggered by SKB BIO's 2025 financial results, which showed revenue growth of 6.5% year-over-year but a widening of net losses to 382 million yuan from 267 million yuan, as authorization and milestone income declined significantly while research and commercialization expenses remained high.</p><p>The sell-off in SKB BIO also occurred amid general weakness in the biotechnology sector during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1113614353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113614353","pubTimestamp":1779948634,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SKB BIO's stock price plummeted 5.02% during intraday trading on Thursday, marking a significant downward movement for the biopharmaceutical company.The sharp decline follows a period of strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"个股追踪|SKB生物盘中暴跌5.02%，尽管此前临床数据反弹，但跌幅扩大后获利了结袭来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"SKB BIO's stock price plummeted 5.02% during intraday trading on Thursday, marking a significant downward movement for the biopharmaceutical company.The sharp decline follows a period of strong performance driven by positive clinical data presented at the ASCO annual meeting and a target price increase by Nomura. However, recent reports highlighting a broader deceleration within the Kelun group have prompted investors to reassess the company's fundamentals, leading to profit-taking. This reassessment was triggered by SKB BIO's 2025 financial results, which showed revenue growth of 6.5% year-over-year but a widening of net losses to 382 million yuan from 267 million yuan, as authorization and milestone income declined significantly while research and commercialization expenses remained high.The sell-off in SKB BIO also occurred amid general weakness in the biotechnology sector during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}